CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
Published on April 30, 2024
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
680 East Colorado Boulevard, Suite 180
Pasadena, California 91101
April 30, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E.
Washington, D.C. 20549
| Re: | Lixte Biotechnology Holdings, Inc. | |
| Registration Statement on Form S-3 | ||
| Filed April 23, 2024 | ||
| File No. 333-278874 |
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, Lixte Biotechnology Holdings, Inc., a Delaware corporation, respectfully requests that the effective date of the above-referenced Registration Statement be accelerated so that the same will become effective at 4:00 p.m., Eastern Time, on Thursday, May 2, 2024, or as soon thereafter as is practicable. Please call our counsel, David Ficksman of TroyGould PC, at 818 469 4200 to provide notice of effectiveness.
| Very truly yours, | ||
| LIXTE BIOTECHNOLOGY HOLDINGS, INC. | ||
| By: | /s/ Bastiaan van der Baan | |
| Bastiaan van der Baan | ||
| Chief Executive Officer | ||